Pair page
GHRP-2 with Ipamorelin
Mechanism-tag overlap and published literature for GHRP-2 and Ipamorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrelin-receptor-agonist
growth-hormone-secretagogue
selective-ghrelin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GHRP-2 and Ipamorelin have published these mechanism-level observations. Not a co-administration recommendation.
Modern selective alternative. Most users picking between the two GHRPs choose ipamorelin for cleaner chronic profile, GHRP-2 for slightly stronger acute GH response.
Quick facts
GHRP-2
Ipamorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2001 | GHRP-2 | Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 1… PMID 11238504 | human study |
| 2005 | GHRP-2 | Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-E492. PMID: 15507534. PMID 15507534 | preclinical, in vivo |
| 2004 | GHRP-2 | Doi N, Furukawa M, Sato C, Sasaki M, et al. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857-867. PMID: 15646370. (Foundational pharmacology characterization by Kaken.) PMID 15646370 | mechanism / discovery |
| 1999 | GHRP-2 | Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. (Ghrelin discovery — endogenous ligand.) PMID 10604470 | mechanism / discovery |
| 1996 | GHRP-2 | Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. (GHS-R1a cloning.) PMID 8688086 | mechanism / discovery |
| 2017 | GHRP-2 | Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Medicc Rev. 2017. PMC5392015. (Class review of cytoprotective evidence.) | review |
| 2026 | GHRP-2 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (GHRP family banned under S2.) | regulatory / registry |
| 2025 | GHRP-2 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026. | regulatory / registry |
| — | GHRP-2 | Thomas A, Höppner S, Geyer H, et al. Determination of growth hormone-releasing peptides in serum by LC-MS/MS for sports drug testing. (WADA detection methodology applicable to GHRP-2.) | regulatory / registry |
| 2004 | GHRP-2 | Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-880. PMID: 15646371. (Safety pharmacology evaluation.) PMID 15646371 | research article |
| 2004 | GHRP-2 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP 102, WAY GPA 748. Drugs R D. 2004;5(4):236-239. PMID: 15230633. (Drug development profile.) PMID 15230633 | research article |
| 2001 | GHRP-2 | Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297568. PMID 11297568 | research article |
| 2014 | Ipamorelin | Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 2… PMID 25331030 | human trial |
| — | Ipamorelin | ClinicalTrials.gov. Study of IPAMORELIN on the Management of Postoperative Ileus Following Partial Bowel Resection. NCT00672074. | human trial |
| 2008 | Ipamorelin | Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008;159(5):547-554. PMID: 18728125. PMID 18728125 | human study |
| 2008 | Ipamorelin | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485. (MK-677 comparator data.) PMID 18981485 | human study |
| 2001 | Ipamorelin | Ghigo E, Arvat E, Giordano R, et al. Biologic activities of growth hormone secretagogues in humans. Endocrine. 2001;14(1):87-93. PMID: 11322506. PMID 11322506 | human study |
| 1999 | Ipamorelin | Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. PMID 10496658 | human study |
| 2012 | Ipamorelin | Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. PMID: 27186126. PMID 27186126 | preclinical, in vivo |
| 2000 | Ipamorelin | Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840. PMID 10828840 | preclinical, in vivo |
| 2020 | Ipamorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi: 10.1002/rco2.9. | mechanism / discovery |
| 1998 | Ipamorelin | Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. (The foundational discovery paper; establishes the selectivity claim.) PMID 9849822 | mechanism / discovery |
| 2026 | Ipamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | Ipamorelin | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have GHRP-2 and Ipamorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of GHRP-2 and Ipamorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GHRP-2 and Ipamorelin share?
GHRP-2 and Ipamorelin share these mechanism tags on their Kalios profiles: growth-hormone-secretagogue. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of GHRP-2 and Ipamorelin?
GHRP-2: Investigational (Category 2 bulk). Ipamorelin: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GHRP-2 and Ipamorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GHRP-2 profile and the Ipamorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026